The Nox4 Inhibitor GKT137831 Attenuates Hypoxia-Induced Pulmonary Vascular Cell Proliferation
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Increased NADP reduced (NADPH) oxidase 4 (Nox4) and reduced expression of the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) contribute to hypoxia-induced pulmonary hypertension (PH). To examine the role of Nox4 activity in pulmonary vascular cell proliferation and PH, the current study used a novel Nox4 inhibitor, GKT137831, in hypoxia-exposed human pulmonary artery endothelial or smooth muscle cells (HPAECs or HPASMCs) in vitro and in hypoxia-treated mice in vivo. HPAECs or HPASMCs were exposed to normoxia or hypoxia (1% O(2)) for 72 hours with or without GKT137831. Cell proliferation and Nox4, PPARγ, and transforming growth factor (TGF)β1 expression were measured. C57Bl/6 mice were exposed to normoxia or hypoxia (10% O(2)) for 3 weeks with or without GKT137831 treatment during the final 10 days of exposure. Lung PPARγ and TGF-β1 expression, right ventricular hypertrophy (RVH), right ventricular systolic pressure (RVSP), and pulmonary vascular remodeling were measured. GKT137831 attenuated hypoxia-induced H(2)O(2) release, proliferation, and TGF-β1 expression and blunted reductions in PPARγ in HPAECs and HPASMCs in vitro. In vivo GKT137831 inhibited hypoxia-induced increases in TGF-β1 and reductions in PPARγ expression and attenuated RVH and pulmonary artery wall thickness but not increases in RVSP or muscularization of small arterioles. This study shows that Nox4 plays a critical role in modulating proliferative responses of pulmonary vascular wall cells. Targeting Nox4 with GKT137831 provides a novel strategy to attenuate hypoxia-induced alterations in pulmonary vascular wall cells that contribute to vascular remodeling and RVH, key features involved in PH pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, so far no direct antioxidative side effects of GKT 137831 were reported [392] highlighting this substance as the most promising inhibitor for Nox enzymes not only in vitro but also in vivo [94,409,411,412,413,414].”
From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [413]
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989 · cited 6×
“NADPH oxidases catalyze the reduction of molecular oxygen to generate superoxide (O2 ), hydrogen peroxide (H2O2), or secondary oxidants (7).”
BackgroundInfluentialHumbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Nihon-Kokyuki-Gakkai (2011) · Cited by 1,301
Vascular NAD(P)H oxidases: specific features, expression, and regulation
Lassègue, B., & Clempus, R. E. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00758.2002 · Cited by 1,032 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundGriendling, K. K., Sorescu, D., Lassègue, B., & Ushio-Fukai, M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2175 · Cited by 955 · cited 1×
“, c-fos, c-jun, c-myc), and inactivation of protein tyrosine phosphatases (40, 41).”
BackgroundSuperoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis
Sorescu, D., Weiss, D., Lassègue, B., Clempus, R. E., Szöcs, K., Sorescu, G. P., Valppu, L., Quinn, M. T., Lambeth, J. D., Vega, J. D., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012917.74432.66 · Cited by 847 · cited 5×
“As the predominant Nox isoform expressed in VSMCs and ECs, Nox4 constitutes an attractive target for PH therapy.”
BackgroundInfluentialNox proteins in signal transduction
Brown, D. I., & Griendling, K. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.023 · Cited by 832 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundCucoranu, I., Clempus, R., Dikalova, A., Phelan, P. J., Ariyan, S., Dikalov, S., & Sorescu, D. (2005) · Circulation Research · doi:10.1161/01.res.0000187457.24338.3d · Cited by 786
Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases
Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., & Knaus, U. G. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.023 · Cited by 783 · cited 2×
“regulates Nox4 in the lung (10), that Nox4 generates H2O2 (26, 27), and that H2O2 reduces PPARg expression in endothelial cells (42), these findings indicate that Nox4-derived ROS mediate”
BackgroundApocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
Heumüller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H. H. W., Busse, R., Schröder, K., & Brandes, R. P. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100214 · Cited by 735 · cited 1×
“Apocynin also functions as an antioxidant in vascular ECs and SMCs, cells that lack the myeloperoxidase activity necessary for apocynin activation (37).”
Background
Cited by
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Functions of ROS in Macrophages and Antimicrobial Immunity
Herb, M., & Schramm, M. (2021) · Antioxidants · doi:10.3390/antiox10020313 · Cited by 633
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
“Another role for NOX4 in pulmonary vessels was suggested, as GKT137831 treatment prevented hypoxia-induced right ventricle hypertrophy, thereby attenuating pulmonary hypertension (65).”
BackgroundNADPH Oxidases in Vascular Pathology
Konior, A., Schramm, A., Czesnikiewicz-Guzik, M., & Guzik, T. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5607 · Cited by 452
Pulmonary Arterial Hypertension: The Clinical Syndrome
Lai, Y.-C., Potoka, K. C., Champion, H. C., Mora, A. L., & Gladwin, M. T. (2014) · Circulation Research · doi:10.1161/circresaha.115.301146 · Cited by 402
“RNA–mediated knockdown of Nox4 or Nox4 inhibitor GKT137831 attenuated vascular remodeling.(104,105) A cross-”
BackgroundJin, Y., Ji, W., Yang, H., Chen, S., Zhang, W., & Duan, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00454-7 · Cited by 399
Cervantes Gracia, K., Llanas-Cornejo, D., & Husi, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6020022 · Cited by 307
“An upregulation of NOX2 and NOX4 is found in PAH, and their inhibition was demonstrated to reverse PAH in animal models [89,90].”
BackgroundOxidative Stress in Pulmonary Fibrosis
Otoupalova, E., Smith, S., Cheng, G., & Thannickal, V. J. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190017 · Cited by 262
“NOX4 is induced by chronic hypoxia and mediates vascular smooth muscle proliferation in pulmonary artery, while a NOX4 inhibitor reverses this effect (181, 370).”
Zhao, Q. D., Viswanadhapalli, S., Williams, P., Shi, Q., Tan, C., Yi, X., Bhandari, B., & Abboud, H. E. (2015) · Circulation · doi:10.1161/circulationaha.114.011079 · Cited by 243
Role of NADPH Oxidases in Liver Fibrosis
Paik, Y.-H., Kim, J., Aoyama, T., De Minicis, S., Bataller, R., & Brenner, D. A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5619 · Cited by 219
“GKT137831 attenuates hypoxia-induced H2O2 release, proliferation, and TGF-b1 expression in human pulmonary artery endothelial or smooth muscle cells (79).”
BackgroundGoncharov, D. A., Kudryashova, T. V., Ziai, H., Ihida-Stansbury, K., DeLisser, H., Krymskaya, V. P., Tuder, R. M., Kawut, S. M., & Goncharova, E. A. (2014) · Circulation · doi:10.1161/circulationaha.113.004581 · Cited by 200
Gestational Hypoxia and Developmental Plasticity
Ducsay, C. A., Goyal, R., Pearce, W. J., Wilson, S., Hu, X.-Q., & Zhang, L. (2018) · Physiological Reviews · doi:10.1152/physrev.00043.2017 · Cited by 198
Roles of reactive oxygen species in inflammation and cancer
Yu, Y., Liu, S., Yang, L., Song, P., Liu, Z., Liu, X., Yan, X., & Dong, Q. (2024) · MedComm · doi:10.1002/mco2.519 · Cited by 164
Therapeutic potential of nadph oxidase 1/4 inhibitors
Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13532 · Cited by 163
Self-citationResponses to reductive stress in the cardiovascular system
Handy, D. E., & Loscalzo, J. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.006 · Cited by 147
“In both hypoxia-induced pulmonary hypertension, as well as in the model of persistent pulmonary hypertension of the newborn (PPHN), Nox4 upregulation was associated with increased hydrogen peroxide, proliferation of vascular cells, and the vascular remodeling associated with disease [67, 68].”
BackgroundNADPH oxidases: key modulators in aging and age-related cardiovascular diseases?
Sahoo, S., Meijles, D. N., & Pagano, P. J. (2016) · Clinical Science · doi:10.1042/cs20150087 · Cited by 146
“Similarly, GKT137831 inhibited ROS production and attenuated diabetes-induced macrophage infiltration, inflammation and fibrosis associated with atherosclerotic plaque formation in ApoE−/− mice as well as attenuated hypoxia-induced H2O2 release and improved indices of ventricular remodelling and pulmonary artery wall…”
BackgroundInfluentialAmini‐Nik, S., Yousuf, Y., & Jeschke, M. G. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.017 · Cited by 153
“In several preclinical models, GKT137831 has been shown to be effective in treating idiopathic pulmonary fibrosis, liver fibrosis, and diabetic nephropathy [236, 247-249].”
NADPH oxidases and vascular remodeling in cardiovascular diseases
García‐Redondo, A. B., Aguado, A., Briones, A. M., & Salaíces, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.015 · Cited by 146
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Estornut, C., Milara, J., Bayarri, M. A., Belhadj, N., & Cortijo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794997 · Cited by 161
“These Genkyotex compounds have also been reported to have protective effects in different pre-clinical in vitro and in vivo studies (Carnesecchi et al., 2011; Green et al., 2012; Jiang et al., 2012; Wan et al., 2016; Tanaka et al., 2017; Cui et al., 2018) (Figure 1).”
BackgroundSuresh, K. S., & Shimoda, L. A. (2016) · Comprehensive physiology · doi:10.1002/cphy.c140049 · Cited by 203
NADPH Oxidase, NOX1, Mediates Vascular Injury in Ischemic Retinopathy
Wilkinson-Berka, J. L., Deliyanti, D., Rana, I., Miller, A. G., Agrotis, A., Armani, R., Szyndralewiez, C., Wingler, K., Touyz, R. M., Cooper, M. E., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5357 · Cited by 122
“Indeed, this compound is an orally active NOX inhibitor with a relative specificity for NOX1 and NOX4 (4, 19).”
Self-citationBarman, S. A., Chen, F., Su, Y., Dimitropoulou, C., Wang, Y., Catravas, J. D., Han, W., Orfi, L., Szantai-Kis, C., Keri, G., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303848 · Cited by 121
“In our study, a functional role for Nox4 can be deduced from the use of Nox4/1 inhibitor GKT136901, which is not selective for Nox2,(54) and also from other studies using GKT137831, which has been shown to be effective in a mouse model of PH.(20) Nox4 has gained considerable attention as a primary source of ROS and ce…”
Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity
Palma, G., Sorice, G. P., Genchi, V. A., Giordano, F., Caccioppoli, C., D’Oria, R., Marrano, N., Biondi, G., Giorgino, F., & Perrini, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137349 · Cited by 140
“NOX4-mediated inhibition of caspase 1 activation reduced adipocyte dysfunction in vitro, ameliorated propensity for obesity in HFD-fed mice, and attenuated pulmonary hypertension in mice exposed to hypoxia, thereby preventing lung dysfunction [165,166].”
BackgroundAn Inhibitor of NADPH Oxidase-4 Attenuates Established Pulmonary Fibrosis in a Rodent Disease Model
Jarman, E. R., Khambata, V. S., Cope, C., Jones, P., Roger, J., Ye, L. Y., Duggan, N., Head, D., Pearce, A., Press, N. J., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0174oc · Cited by 115
The human Nox4: gene, structure, physiological function and pathological significance
Guo, S., & Chen, X. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1036276 · Cited by 113
“Therefore, TGF-b1 might serve as both the upstream and downstream of Nox4 signaling [52,61].”
BackgroundNADPH Oxidases in Lung Health and Disease
Bernard, K. F., Hecker, L., Luckhardt, T., Cheng, G., & Thannickal, V. J. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5608 · Cited by 114
“AHR¼ airway hyperresponsiveness AKT¼protein kinase B ALI¼ acute lung injury AML¼ acute myeloid leukemia AP-1¼ activator protein 1 ARDS¼ acute respiratory distress syndrome ASL¼ airway surface liquid CEM¼ caveolin-enriched microdomain CGD¼ chronic granulomatous disease COPD¼ chronic obstructive pulmonary disease CS¼ ci…”
BackgroundInfluentialKnock, G. A. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.09.029 · Cited by 109
Chen, F., Li, X., Aquadro, E., Haigh, S. B., Zhou, J., Stepp, D. W., Weintraub, N. L., Barman, S. A., & Fulton, D. J. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.08.003 · Cited by 111
“[2,68,69], and genetic deletion or pharmacological inhibition of Nox enzymes reduces pulmonary hypertension [2,15,17,18].”
BackgroundCaveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species
Chen, F., Barman, S. A., Yu, Y., Haigh, S., Wang, Y., Dou, H., Bagi, Z. A., Han, W., Su, Y., & Fulton, D. J. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.04.029 · Cited by 108
“Nox isoforms are major sources of cellular ROS production[15] and we observed higher levels of expression of both Nox2 and Nox4 in hypertensive PA which is consistent with previously published data [21, 49].”
Rutin protects endothelial dysfunction by disturbing Nox4 and ROS-sensitive NLRP3 inflammasome
Wang, W., Wu, Q., Sui, Y., Wang, Y., & Qiu, X. Y. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.134 · Cited by 105
trans-Endothelial neutrophil migration activates bactericidal function via Piezo1 mechanosensing
Mukhopadhyay, A., Tsukasaki, Y., Chan, W. C., Le, J., Kwok, M. L., Zhou, J., Natarajan, V., Mostafazadeh, N., Maienschein‐Cline, M., Papautsky, I., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.007 · Cited by 111
NADPH Oxidases and Their Role in Atherosclerosis
Poznyak, A. V., Grechko, A. V., Orekhova, V. A., Khotina, V. A., Ivanova, E. A., & Orekhov, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8070206 · Cited by 105
Tsubouchi, K., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Sato, N., Yoshida, M., Kurita, Y., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1328348 · Cited by 103
“To further confirm the involvement of NOX4 in TGFBinduced myofibroblast differentiation, GKT137831, a NOX4 inhibitor was used.(20) Efficient inhibition of myofibroblast differentiation was observed by treatment with GKT137831 (Fig.”
BackgroundReactive Oxygen Species: Not Omnipresent but Important in Many Locations
Herb, M., Gluschko, A., & Schramm, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.716406 · Cited by 87
The Quest for Selective Nox Inhibitors and Therapeutics: Challenges, Triumphs and Pitfalls
Cifuentes-Pagano, E., Meijles, D. N., & Pagano, P. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5620 · Cited by 84
“GKT137831 was also used to study the role of Nox4 in hypoxia-induced pulmonary vascular cell proliferation (64) where it attenuated hypoxiainduced H2O2 production, proliferation, and TGF-b1 expression.”
BackgroundTargeting mitochondrial reactive oxygen species to modulate hypoxia-induced pulmonary hypertension
Adesina, S. E., Kang, B., Bijli, K. M., Ma, J., Cheng, J., Murphy, T. C., Hart, C. M., & Sutliff, R. L. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.042 · Cited by 90
Self-citationHood, K. Y., Montezano, A. C. I., Harvey, A., Nilsen, M., MacLean, M. R., & Touyz, R. M. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07668 · Cited by 84
Deliyanti, D., & Wilkinson-Berka, J. L. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0363-z · Cited by 76
“The therapeutic potential of GKT137831 has been demonstrated in various animal models of disease [19, 29–32] and is currently being evaluated in the clinic [16].”
BackgroundManea, S.-A., Antonescu, M.-L., Fenyo, I. M., Raicu, M., Simionescu, M., & Manea, A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.011 · Cited by 74
Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension
Fulton, D. J., Li, X., Bordán, Z., Haigh, S. B., Bentley, A., Chen, F., & Barman, S. A. (2017) · Antioxidants · doi:10.3390/antiox6030054 · Cited by 82
“Hypoxia Mouse, Human EC ↑ Nox4 GKT137831 (Nox4/Nox1) ↓ pulmonary hypertension, ↓ PASMC proliferation [77]”
BackgroundMethodJeong, B. Y., Lee, H. Y., Park, C. G., Kang, J., Yu, S., Choi, D. R., Han, S. Y., Park, M. H., Cho, S.-K., Lee, S. Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191034 · Cited by 77
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and liver fibrosis: A review
Mortezaee, K. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3351 · Cited by 72
Somanna, N. K., Valente, A. J., Krenz, M., Fay, W. P., Delafontaine, P., & Chandrasekar, B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25210 · Cited by 75
“This dual inhibitor also attenuates hypoxia-induced pulmonary vascular cell proliferation (Green et al., 2012).”
BackgroundLu, X., Bijli, K. M., Ramirez, A. M., Murphy, T. C., Kleinhenz, J., & Hart, C. M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.013 · Cited by 71
“Reduced PPARγ expression has also been observed in the vascular lesions of patients with idiopathic pulmonary arterial hypertension, in a rat model of severe PH caused by treatment with hypoxia and a vascular endothelial growth factor receptor antagonist [13], and in pulmonary artery endothelial cells isolated from pa…”
BackgroundMethodInfluentialSelf-citationThannickal, V. J., Jandeleit‐Dahm, K., Szyndralewiez, C., & Török, N. J. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17649 · Cited by 65
Self-citationFocus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development
Rafikova, O., Ghouleh, I. A., & Rafikov, R. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7673 · Cited by 70
Current status of NADPH oxidase research in cardiovascular pharmacology
Álvarez, E., Rodiño-Janeiro, Paradela-Dobarro, Castiñeiras-Landeira, Raposeiras‐Roubín, S., & González‐Juanatey, J. R. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33053 · Cited by 78
“All together, this makes it a good drug candidate as a NADPH oxidase inhibitor, and it has been shown to attenuate hypoxia-induced pulmonary vascular cell proliferation in mice, suggesting its value in pulmonary hypertension.(197) S17834 blocks NADPH oxidase activity in intact endothelial cells and in isolated endothe…”
BackgroundFunction of NADPH Oxidases in Diabetic Nephropathy and Development of Nox Inhibitors
Lee, S. R., An, E. J., Kim, J., & Bae, Y. S. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2019.188 · Cited by 69
Piera-Velázquez, S., & Jiménez, S. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204791 · Cited by 69
Siqués, P., Pena, E., Brito, J., & Alam, S. E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.690341 · Cited by 64
Ghouleh, I. A., Sahoo, S., Meijles, D. N., Amaral, J. H., de Jesus, D. S., Sembrat, J., Rojas, M. M., Goncharov, D. A., Goncharova, E. A., & Pagano, P. J. (2017) · Clinical Science · doi:10.1042/cs20160812 · Cited by 60
Sampson, N., Berger, P., & Zenzmaier, C. (2014) · BioMed Research International · doi:10.1155/2014/131737 · Cited by 60
Role of Reactive Oxygen Species in Neonatal Pulmonary Vascular Disease
Wedgwood, S., & Steinhorn, R. H. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5785 · Cited by 51
“Administration of the Nox1/Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary artery (PA) wall thickness and right ventricular hypertrophy in mice (73), while reduced ROS levels have been detected in several animal models treated with the pan-Nox inhibitor VAS 2870 (6).”
BackgroundFulton, D. J., Li, X., Bordán, Z., Wang, Y., Mahboubi, K., Rudic, R. D., Haigh, S. B., Chen, F., & Barman, S. A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7753 · Cited by 56
“Increased expression of NOX4 has been reported in human PAH (105), and several lines of evidence support an important role for NOX4 in the pathogenesis of PAH in rats and humans (10, 105), but this remains controversial in mice (50, 115, 166).”
BackgroundCellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia
Shimoda, L. A. (2020) · Physiology · doi:10.1152/physiol.00039.2019 · Cited by 59
Piera-Velázquez, S., Makul, A., & Jiménez, S. A. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39242 · Cited by 59
“displaying very high NOX4/NOX1 specificity [36–40].”
Transforming growth factor‐β1 requires NADPH oxidase 4 for angiogenesisin vitroandin vivo
Peshavariya, H., Chan, E. C., Liu, G., Jiang, F., & Dusting, G. J. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12263 · Cited by 51
“Indeed, recently it has been shown that GKT137831, an inhibitor of Nox1 and Nox4, attenuated hypoxia-induced TGF-b1 expression and proliferation of human pulmonary artery endothelial and smooth muscle cells in vitro, as well as attenuated pulmonary artery wall thickening and vascular remodelling in vivo, features whic…”
BackgroundNox4-Generated Superoxide Drives Angiotensin II-Induced Neural Stem Cell Proliferation
Topchiy, E., Panzhinskiy, E., Griffin, W. S. T., Barger, S. W., Das, M., & Zawada, W. M. (2013) · Developmental Neuroscience · doi:10.1159/000350502 · Cited by 49
Green, D. E., Murphy, T. C., Kang, B., Searles, C. D., & Hart, C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133391 · Cited by 50
“This dose was chosen because previous studies from our lab demonstrated that hypoxia-induced pulmonary hypertension, right ventricular hypertrophy and vascular remodeling were attenuated at this drug dose [5, 6].”
BackgroundMethodSelf-citationPlumbagin Protects Mice from Lethal Sepsis by Modulating Immunometabolism Upstream of PKM2
Zhang, Z., Deng, W., Kang, R., Xie, M., Billiar, T. R., Wang, H., Cao, L., & Tang, D. (2016) · Molecular Medicine · doi:10.2119/molmed.2015.00250 · Cited by 50
Xue, K., Zhang, J., Li, C., Li, J., Wang, C., Zhang, Q., Chen, X., Yu, X., Sun, L., & Yu, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14313 · Cited by 58
Signaling pathways and targeted therapy for pulmonary hypertension
Adu‐Amankwaah, J., Shi, Y., Song, H., Ma, Y., Liu, J., Wang, H., Yuan, J., Sun, K., Hu, Q., & Tan, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02287-8 · Cited by 63
Ma, C., Zhang, C., Ma, M., Zhang, L., Zhang, L., Zhang, F., Chen, Y., Cao, F., Li, M., Wang, G., et al. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1541-5 · Cited by 48
Mitochondrial Metabolism, Redox, and Calcium Homeostasis in Pulmonary Arterial Hypertension
Liang, S., Yegambaram, M., Wang, T., Wang, J., Black, S. M., & Tang, H. (2022) · Biomedicines · doi:10.3390/biomedicines10020341 · Cited by 46
“An inhibitor of NOX4 GKT137831 reduces hypoxia-induced H2O2 release, the hyperproliferation of PVCs, and attenuates hypoxia-induced PAH in mice [189].”
BackgroundPorter, K. M., Kang, B., Adesina, S. E., Murphy, T. C., Hart, C. M., & Sutliff, R. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098532 · Cited by 45
“HPAEC, passages 3-8, were exposed to hypoxia in a Biospherix exposure chamber (Lacona, NY) as previously described [18,19].”
BackgroundMethodSelf-citationThe Role of NOX4 and TRX2 in Angiogenesis and Their Potential Cross-Talk
Chen, C., Li, L., Zhou, H., & Min, W. (2017) · Antioxidants · doi:10.3390/antiox6020042 · Cited by 43
“Consistent with this notion, the NOX4 inhibitor GKT137831 attenuates hypoxia-induced H2O2 release, proliferation and TGF-β1 expression and blunts reductions in PPARγ in vitro and in vivo [47].”
BackgroundInfluentialOgola, B. O., Zimmerman, M. A., Sure, V. N. L. R., Gentry, K. M., Duong, J. L., Clark, G. L., Miller, K. S., Katakam, P. V. G., & Lindsey, S. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00586 · Cited by 46
“Nox1 and 4 may interact in the regulation of ROS since nonspecific Nox1/4 inhibitors GKT136901 or GKT137831 attenuate oxidative stress (44, 45, 68).”
BackgroundHarrison, I. P., & Selemidis, S. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12238 · Cited by 43
“A recent study showed that GK-136901 may prevent high glucose-induced ROS-dependent changes in the kidney.134 Green et al.135 showed that GKT137831, a novel Nox4 inhibitor, attenuates hypoxia-induced H2O2 release, proliferation and TGF-b1 expression, and blunts reductions in peroxisome proliferator-activated receptor…”
BackgroundInfluentialGalectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension
Luo, H., Liu, B., Zhao, L., He, J., Li, T., Zha, L., Li, X., Qi, Q., Liu, Y., & Yu, Z. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.07.009 · Cited by 45
Bijli, K. M., Kleinhenz, J., Murphy, T. C., Kang, B., Adesina, S. E., Sutliff, R. L., & Hart, C. M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.12.019 · Cited by 41
“Levels of PPARγ are attenuated in pulmonary artery endothelial cells isolated from patients with idiopathic pulmonary arterial hypertension [15].”
InfluentialSelf-citationRegulation of Smooth Muscle Cell Proliferation by NADPH Oxidases in Pulmonary Hypertension
Huetsch, J., Suresh, K. S., & Shimoda, L. A. (2019) · Antioxidants · doi:10.3390/antiox8030056 · Cited by 47
“Hypoxia upregulates Nox4 via several pathways, including a proline-rich tyrosine kinase 2 (Pyk2)-extracellular signal-regulated kinase (ERK 1/2)-nuclear factor-kappa B (NF-kB) axis, hypoxia-inducible transcription factor 1 (HIF-1), transforming growth factor β1 (TGF-β1), and thrombospondin-1 (TSP-1).”
BackgroundInfluentialUrea-induced ROS accelerate senescence in endothelial progenitor cells
D’Apolito, M., Colia, A. L., Lasalvia, M., Capozzi, V., Falcone, M. P., Pettoello‐Mantovani, M., Brownlee, M., Maffione, A. B., & Giardino, I. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.028 · Cited by 45
Wound Healing After Alkali Burn Injury of the Cornea Involves Nox4-Type NADPH Oxidase
Hakami, N., Dusting, G. J., Chan, E. C., Shah, M. H., & Peshavariya, H. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.12.20 · Cited by 49
Lakhkar, A., Dhagia, V., Joshi, S. R., Gotlinger, K. H., Patel, D., Sun, D., Wolin, M. S., Schwartzman, M. L., & Gupte, S. A. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00961.2015 · Cited by 44
Lysocardiolipin acyltransferase regulates TGF-β mediated lung fibroblast differentiation
Huang, L. S., Jiang, P., Feghali‐Bostwick, C. A., Reddy, S. P., Garcia, J. G. N., & Natarajan, V. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.023 · Cited by 38
Zeng, S.-Y., Yang, L., Yan, Q., Gao, L., Lu, H., & Yan, P. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.077 · Cited by 42
Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells
Blum, J. I., Bijli, K. M., Murphy, T. C., Kleinhenz, J. M., & Hart, C. M. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.019 · Cited by 36
“In previous studies, we showed that stimulating the metabolic regulator, PPARγ attenuates PH.(10,31,36) Mechanisms for these protective effects involve alterations in the transcriptional and posttranscriptional regulation of important mediators in PH pathogenesis such as endothelin-1, Nox4 and thrombospondin.”
BackgroundMethodInfluentialSelf-citationNADPH Oxidase 4 is Not Involved in Hypoxia‐Induced Pulmonary Hypertension
Veith, C., Kraut, S., Wilhelm, J., Sommer, N., Quanz, K., Seeger, W., Brandes, R. P., Weißmann, N., & Schröder, K. (2016) · Pulmonary Circulation · doi:10.1086/687756 · Cited by 37
“dysregulated in PH pathogenesis and critically involved in PASMC proliferation.(20,21,23) Importantly, PASMC constriction and prolifera-”
BackgroundWang, J., Liu, Y., Shen, H., Li, H., Wang, Z., & Chen, G. (2019) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-030-04615-6_8 · Cited by 38
NOX4 expression and distal arteriolar remodeling correlate with pulmonary hypertension in COPD
Guo, X., Fan, Y., Cui, J., Hao, B., Zhu, L., Sun, X., He, J., Yang, J., Dong, J., Wang, Y., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0680-y · Cited by 34
“vascular cell proliferation [58], and the cyclic stretch induced mitochondrial ROS and NOX4 signaling in PASMCs [59].”
BackgroundRedox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension
Tseng, V., Sutliff, R. L., & Hart, C. M. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7695 · Cited by 36
“These studies demonstrate the remarkable range of mechanisms by which PPARc activation is therapeutic in PH, including abatement of ROS production (112, 124, 130), improved NO signaling (98, 104), inhibition of the endothelin pathway (87, 88, 90, 93, 110), normalization of metabolic derangements (27, 103), and cell cy…”
Self-citationZhang, M., Chang, Z., Zhao, F., Zhang, P., Hao, Y., Yan, L., Liu, N., Wang, J., Bo, L., Ma, P., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00013 · Cited by 33
“In PAH, Nox2, and Nox4 are up-regulated (Green et al., 2012; Wedgwood et al., 2013) and implicated in the development of increased pulmonary artery resistance and pressure (Barman et al., 2014; Wu et al., 2017a).”
BackgroundGreen, D. E., Murphy, T. C., Kang, B., Bedi, B., Yuan, Z., Sadikot, R. T., & Hart, C. M. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00532.2016 · Cited by 33
Self-citationOosterheert, W., Reis, J., Gros, P., & Mattevi, A. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00400 · Cited by 30
Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells
Appukuttan, B., Ma, Y., Stempel, A. J., Ashander, L. M., Deliyanti, D., Wilkinson‐Berka, J. L., & Smith, J. R. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13155 · Cited by 34
“comparison to control animals, Nox4 gene-deleted mice or mice treated with Nox4 inhibitor demonstrate reduced capillary growth in the gastrocnemius muscle, in response to running exercise on a wheel or treadmill(33); poor recovery of capillary density and blood flow in the leg following femoral artery ligation(34); an…”
BackgroundNOX4, a new genetic target for anti‐cancer therapy in digestive system cancer
Tang, C., Gao, Y. J., & Ge, Z. Z. (2018) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12651 · Cited by 35
The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Lung Architecture Remodeling
Harijith, A. K., Natarajan, V., & Fu, P. (2017) · Antioxidants · doi:10.3390/antiox6040104 · Cited by 31
“Targeting Nox1/4 with a pharmacological inhibitor, GKT137831, attenuated hypoxia-induced pulmonary smooth muscle cell proliferation, vascular remodeling and the development of PAH [133].”
BackgroundReactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses
Mannan, A., Germon, Z. P., Chamberlain, J., Sillar, J. R., Nixon, B., & Dun, M. D. (2021) · Antioxidants · doi:10.3390/antiox10101616 · Cited by 31
Redox Regulation of Ion Channels and Receptors in Pulmonary Hypertension
Weise-Cross, L., Resta, T. C., & Jernigan, N. L. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7699 · Cited by 27
“NOX4-derived ROS have been shown to promote vascular remodeling by both PASMC (55, 161) and adventitial fibroblast proliferation (92).”
BackgroundLiu, J., Chandaka, G. K., Zhang, R., & Parfenova, H. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.630 · Cited by 25
Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension
Plecitá‐Hlavatá, L., D’Alessandro, A., Kasmi, K. E., Li, M., Zhang, H., Ježek, P., & Stenmark, K. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63245-2_14 · Cited by 25
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 28
NADPH oxidase-mediated endothelial injury in HIV- and opioid-induced pulmonary arterial hypertension
Agarwal, S., Sharma, H., Chen, L., & Dhillon, N. K. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00480.2019 · Cited by 27
Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension
Barman, S. A., Bordán, Z., Batori, R. K., Haigh, S. B., & Fulton, D. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_2 · Cited by 28
NADPH oxidases—do they play a role in TRPC regulation under hypoxia?
Malczyk, M., Veith, C., SCHERMULY, R. T., Gudermann, T. W., Dietrich, A., Sommer, N., Weißmann, N., & Pak, O. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-015-1731-3 · Cited by 26
“Additionally, ROS can modulate the level of growth factors [66], cytokines, chemokines [5] and activate various”
BackgroundInfluentialTan, H. K., Yao, H., Lie, Z., Chen, G., Lin, S., & Zhang, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10251 · Cited by 28
Peptide inhibition of p22phox and Rubicon interaction as a therapeutic strategy for septic shock
Kim, Y.-R., Koh, H.-J., Kim, J., Yun, J.-S., Jang, K., Lee, J., Jung, J. U., & Yang, C. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.046 · Cited by 23
“Several studies have reported that the NOX1/4 inhibitor, GKT137831, prevents the liver fibrosis and hepatocyte apoptosis, type 1 diabetes mellitus-accelerated atherosclerosis, and, hypertension-mediated inhibition of NOX activity [46-48].”
BackgroundStabilization of p22phox by Hypoxia Promotes Pulmonary Hypertension
Zhang, Z., Trautz, B., Kračun, D., Vogel, F., Weitnauer, M., Hochkogler, K., Petry, A., & Görlach, A. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7482 · Cited by 27
“Further, a chemical inhibitor of NOX1-and NOX4-dependent NADPH oxidases decreased hypoxia-induced right ventricular hypertrophy, although it did not prevent PH and pulmonary vascular remodeling under these conditions (22).”
Kudryashova, T. V., Goncharov, D. A., Pena, A. Z., Ihida‐Stansbury, K., DeLisser, H. M., Kawut, S. M., & Goncharova, E. A. (2015) · Pulmonary Circulation · doi:10.1086/683810 · Cited by 24
Dick, A. S., Ivanovska, J., Kantores, C., Belcastro, R., Tanswell, A. K., & Jankov, R. P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.027 · Cited by 24
Metadata
- Authors
- Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M.
- Affiliations
- Emory University (US)
- Genkyotex (Switzerland) (CH)
- Corresponding author
- Hart, C. Michael
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-01
- Volume
- 47
- Issue
- 5
- Pages
- 718-726
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC3547100
- OpenAlex
- W1990038383
- Cited by
- 146
- References
- 50
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 11 · 2019: 14 · 2018: 18 · 2017: 19 · 2016: 16 · 2015: 11 · 2014: 14 · 2013: 13
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (NHLBI T32, HL081064, HL 60917)
- National Heart, Lung, and Blood Institute (HL-60917, HL-081064, T32HL076118, P01HL081064, R01HL102167, R01HL060917)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074518)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- NOX4, GKT137831, NADPH oxidase inhibitors, hypoxia, pulmonary hypertension, PPARγ, TGF-β1, pulmonary artery endothelial cells, pulmonary artery smooth muscle cells, right ventricular hypertrophy, pulmonary vascular remodeling, hydrogen peroxide
- MeSH terms
- NADPH Oxidase 4, Rosiglitazone, Animals, Cells, Cultured, Endothelium, Vascular, Humans, Hydrogen Peroxide, Hypertension, Pulmonary, Lung, Mice, Inbred C57BL, Pulmonary Artery, Pyrazoles, Pyridines, Pyridones, Cell Hypoxia, Gene Expression, Proliferating Cell Nuclear Antigen, NADPH Oxidases, Ventricular Remodeling, Myocytes, Smooth Muscle, RNA Interference, Endothelial Cells, Thiazolidinediones, Pyrazolones, PPAR gamma, Cell Proliferation, Mice, Transforming Growth Factor beta1, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.